EBITDA: Income before interest, taxes, depreciation and amortization.
BioNexus Gene Lab Corp. (BGLC) had EBITDA of $-0.64M for the most recently reported fiscal quarter, ending 2025-09-30.
| Income Statement Financials | |
$2.54M |
|
$-0.71M |
|
$2.17M |
|
$0.38M |
|
$3.25M |
|
$-0.70M |
|
$-0.01M |
|
$-0.71M |
|
$-0.71M |
|
$-0.71M |
|
$-0.71M |
|
$-0.71M |
|
$-0.71M |
|
$-0.68M |
|
|
EBITDA |
$-0.64M |
1.80M |
|
1.80M |
|
$-0.40 |
|
$-0.40 |
|
| Balance Sheet Financials | |
$5.63M |
|
$1.57M |
|
$1.99M |
|
$7.62M |
|
$0.68M |
|
-- |
|
$0.13M |
|
$0.81M |
|
$6.82M |
|
$6.82M |
|
$6.82M |
|
1.80M |
|
| Cash Flow Statement Financials | |
$-2.80M |
|
$0.95M |
|
$0.03M |
|
$2.89M |
|
$1.36M |
|
$-1.53M |
|
-- |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
8.30 |
|
-- |
|
-- |
|
-- |
|
-- |
|
14.85% |
|
-27.62% |
|
-26.80% |
|
-- |
|
-27.87% |
|
-27.87% |
|
$-2.84M |
|
-- |
|
-- |
|
-- |
|
0.33 |
|
2.15 |
|
1.47 |
|
61.02 |
|
-10.40% |
|
-10.40% |
|
-9.30% |
|
-10.40% |
|
$3.79 |
|
$-1.58 |
|
$-1.56 |
|